New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)

Leukemia

Volumn 28, Issue 3, 2014, Pages 525-542

  Ocio, E M ^a   Richardson, P G ^b   Rajkumar, S V ^c   Palumbo, A ^d   Mateos, M V ^a   Orlowski, R ^e   Kumar, S ^c   Usmani, S ^f,ad   Roodman, D ^g   Niesvizky, R ^h   Einsele, H ⁱ   Anderson, K C ^b   Dimopoulos, M A ^j   Avet Loiseau, H ^k   Mellqvist, U H ^l   Turesson, I ^m   Merlini, G ⁿ   Schots, R ^o   Mccarthy, P ^p   Bergsagel, L ^q   Chim, C S ^r   Lahuerta, J J ^s   Shah, J ^e   Reiman, A ^t   Mikhael, J ^q   Zweegman, S ^u   Lonial, S ^v   Comenzo, R ^w   Chng, W J ^x   Moreau, P ^y   Sonneveld, P ^z   Ludwig, H ^aa   Durie, B G M ^ab   Miguel, J F S ^a,ac   more..

^a Centro de Investigacion del Cancer   (Spain)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF TURIN   (Italy)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g INDIANA UNIVERSITY   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^k UNIVERSITÉ DE TOULOUSE   (France)

^l SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^m LUND UNIVERSITY HOSPITAL   (Sweden)

ⁿ UNIVERSITY OF PAVIA   (Italy)

^o Division of Clinical Haematology Ziekenhuis University   (Belgium)

^p ROSWELL PARK CANCER INSTITUTE   (United States)

^q MAYO CLINIC   (United States)

^r QUEEN MARY HOSPITAL   (Hong Kong)

^s HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^t UNIVERSITY OF NEW BRUNSWICK   (Canada)

^u VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^v Department of Hematology and Medical Oncology Shanghai Chang Zheng Hospital   (United States)

^w TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x Cancer Institute   (Singapore)

^y NANTES UNIVERSITY HOSPITAL   (France)

^z ERASMUS MEDICAL CENTER   (Netherlands)

^aa WILHELMINEN HOSPITAL   (Austria)

^ab Samuel Oschin Comprehensive Cancer Institute   (United States)

^ac UNIVERSITY OF NAVARRA   (Spain)

^ad LEVINE CANCER INSTITUTE   (United States)

more..

Author keywords

Multiple myeloma; New drugs; Phase I clinical trials; Targeted agents

Indexed keywords

AGENTS AFFECTING PROTEIN METABOLISM; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ARRY 520; AVE 1642; CARFILZOMIB; CELL CYCLE SPECIFIC DRUG; CETUXIMAB; DACETUZUMAB; DARATUMUMAB; DASATINIB; DEXAMETHASONE; DINACICLIB; DOVITINIB; ELOTUZUMAB; ENZASTAURIN; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IMMUNOMODULATING AGENT; IXAZOMIB; IXAZOMIB CITRATE; LENALIDOMIDE; LUCATUMUMAB; MASITINIB; MONOCLONAL ANTIBODY; OPROZOMIB; PHOSPHOTRANSFERASE INHIBITOR; PR 047; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; SIGNALING TRANSDUCTION PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

CANCER IMMUNOTHERAPY; DRUG MECHANISM; HUMAN; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; MULTIPLE MYELOMA;

EID: 84895784261     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.350     Document Type: Review

References (200)

1. Greene JA, Jones DS, Podolsky SH. Therapeutic evolution and the challenge of rational medicine. N Engl J Med 2012; 367: 1077-1082.
2. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
3. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
4. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
5. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia 2012; 26: 1153.
6. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
7. Anderson KC. New insights into therapeutic targets in myeloma. Hematol Am Soc Hematol Educ Program 2011; 2011: 184-190.
8. Boyd KD, Davies FE, Morgan GJ. Novel drugs in myeloma: Harnessing tumour biology to treat myeloma. Recent Results Cancer Res 2011; 183: 151-187.
9. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: Mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008; 9: 1157-1165.
10. Arrigo AP, Tanaka K, Goldberg AL, Welch WJ. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 1988; 331: 192-194.
11. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
12. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
13. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
14. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final timeto-event results of the APEX trial. Blood 2007; 110: 3557-3560.
15. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-14379.
16. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-1534.
17. Hideshima T, Richardson PG, Anderson KC. Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol 2003; 7: 191-204.
18. Carvalho P, Goder V, Rapoport TA. Distinct ubiquitin-ligase complexes define convergent pathways for the degradation of ER proteins. Cell 2006; 126: 361-373.
19. Raasi S, Wolf DH. Ubiquitin receptors and ERAD: A network of pathways to the proteasome. Semin Cell Dev Biol 2007; 18: 780-791.
20. Karin M. How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex. Oncogene 1999; 18: 6867-6874.
21. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK et al. An open-label, single-Arm, phase 2 (PX-171-004) study of single-Agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119: 5661-5670.
22. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S et al. A phase 2 study of single-Agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-2825.
23. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K et al. An open-label, single-Arm, phase 2 study of single-Agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012; 158: 739-748.
24. Singhal S, Siegel DS, Martin T, Vij R, Wang L, Jakubowiak AJ et al. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): An updated analysis. ASH Ann Meet Abstr 2011; 118: 1876.
25. Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z et al. Carfilzomib in multiple myeloma patients with renal impairment: Pharmacokinetics and safety. Leukemia 2013; 27: 1707-1714.
26. Wang M, Martin T, Bensinger W, Alsina M, Siegel DSD, Kavalerchik E et al. Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma. ASCO Meet Abstr 2013; 31(15-suppl): 8529.
27. Moreau P, Palumbo AP, Stewart AK, Rajkumar V, Jakubowiak AJ, Halka K et al. A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM). ASCO Meet Abstr 2011; 29(15-suppl): TPS225.
28. Jakubowiak AJ, Dytfeld D, Jagannath S, Vesole DH, Anderson TB, Nordgren BK et al. Final results of a frontline phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM). ASH Ann Meet Abstr 2011; 118: 631.
29. Korde N, Zingone A, Kwok M, Manasanch EE, Wu P, Tageja N et al. Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) in newly diagnosed multiple myeloma (MM) patients. Haematologica 2013; 98: Abstract 228.
30. Sonneveld P, Asselbergs E, Zweegman S, Van der Holt B, Kersten MJ, Vellenga E et al. Carfilzomib combined with thalidomide and dexamethasone (CTD) is an highly effective induction and consolidation treatment in newly diagnosed patients with multiple myeloma (MM) who are transplant candidate. ASH Ann Meet Abstr 2012; 120: 333.
31. Mikhael JR, Reeder CB, Libby III EN, Costa LJ, Bergsagel PL, Buadi F et al. Results from the phase II dose expansion of cyclophosphamide, carfilzomib, thalidomide and dexamethasone (CYCLONE) in patients with newly diagnosed multiple myeloma. ASH Ann Meet Abstr 2012; 120: 445.
32. Bringhen S, Cavallo F, Petrucci MT, Gay F, Federico V, Conticello C et al. Carfilzomib, cyclophosphamide and dexamethasone (CCD) for newly diagnosed multiple myeloma (MM) patients: Initial results of a multicenter, open label phase II study. Haematologica 2013; 98: Abstract S578.
33. Touzeau C, Kolb B, Hulin C, Caillot D, Benboubker L, Tiab M et al. Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial. ASCO Meet Abstr 2013; 31(15-suppl): 8513.
34. Berdeja JG, Hart L, Lamar R, Murphy P, Morgan S, Flinn IW. Phase I/II study of panobinostat and carfilzomib in patients (pts) with relapsed or refractory multiple myeloma (MM), interim phase i safety analysis. ASH Ann Meet Abstr 2012; 120: 4048.
35. Shah JJ, Thomas SK, Weber DM, Wang M, Alexanian R, Qazilbash MH et al. Phase 1/1b study of the efficacy and safety of the combination of panobinostatþcarfilzomib in patients with relapsed and/or refractory multiple myeloma. ASH Ann Meet Abstr 2012; 120: 4081.
36. Kauffman J, Zimmerman T, Jakubowiak A, Rosenbaum C, Lewis C, Harvey RD et al. Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: A multicenter MMRC clinical trial. Haematologica 2013; 98: Abstract P771.
37. Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C et al. A multi-center phase i/ii trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. ASH Ann Meet Abstr 2012; 120: 74.
38. Shah JJ, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH et al. Phase 1 Study of the novel kinesin spindle protein inhibitor ARRY-520þ carfilzomib in patients with relapsed and/or refractory multiple myeloma. ASH Ann Meet Abstr 2012; 120: 4082.
39. Shah JJ, Thomas S, Weber DM, Wang M, Orlowski R. Phase 1 study of the novel kinesin spindle protein inhibitor Arry-520þcarfilzomib(Car) in patients with relapsed and/or refractory multiple myeloma (RRMM). Haematologica 2013; 98: Abstract S579.
40. Zhou HJ, Aujay MA, Bennett MK, Dajee M, Demo SD, Fang Y et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009; 52: 3028-3038.
41. Savona MR, Berdeja JG, Lee SJ, Wong H, Lee JR, Gillenwater HH et al. A phase 1b dose-escalation study of split-dose oprozomib (ONX0912) in patients with hematologic malignancies. ASH Ann Meet Abstr 2012; 120: 203.
42. Kaufman JL, Siegel D, Vij R, Ghobrial IM, Badros AZ, Neuman L et al. Clinical profile of once-daily, modified-release oprozomib tablets in patients with hematologic malignancies: Results of a phase 1b/2 trial. Haematologica 2013; 98: Abstract P233.
43. Kumar S, Bensinger W, Zimmerman TM, Reeder CB, Berenson JR, Berg D et al. Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment. ASCO Meet Abstr 2013; 31(15-suppl): 8514.
44. Lonial S, Baz RC, Wang M, Talpaz M, Liu G, Berg D et al. Phase I study of twice-weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients (pts) with relapsed and/or refractory multiple myeloma (MM). ASCO Meet Abstr 2012; 30(15-suppl): 8017.
45. San Miguel J, Hajek R, Spicka I, Chen C, Echeveste A, Schusterbauer C et al. Oral MLN9708, an investigational proteasome inhibitor, in combination with melphalan and prednisone in patients with previously untreated multiple myeloma: A phase 1 study. Haematologica 2012; 97: Abstract 293.
46. Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Hamadani M, Stewart AK et al. A phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma (MM). ASH Ann Meet Abstr 2012; 120: 332.
47. Richardson PG, Spencer A, Cannell P, Harrison SJ, Catley L, Underhill C et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Ann Meet Abstr 2011; 118: 302.
48. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-Agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
49. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
50. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al. Identification of a primary target of thalidomide teratogenicity. Science 2010; 327: 1345-1350.
51. Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
52. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012; 26: 2326-2335.
53. Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M et al. IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood 2011; 117: 5157-5165.
54. Lopez-Girona A, Heintel D, Zhang LH, Mendy D, Gaidarova S, Brady H et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011; 154: 325-336.
55. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
56. Gandhi AK, Kang J, Capone L, Parton A, Wu L, Zhang LH et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010; 10: 155-167.
57. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69: 7347-7356.
58. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia 2001; 15: 1950-1961.
59. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: Therapeutic implications. Blood 2006; 108: 618-621.
60. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D et al. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-Treated CD20þ tumor cells. Clin Cancer Res 2008; 14: 4650-4657.
61. Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J et al. The anticancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58: 1033-1045.
62. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest 2008; 118: 2427-2437.
63. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142.
64. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132.
65. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA et al. Long-Term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009; 23: 2147-2152.
66. Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 2013; 121: 1961-1967.
67. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008-5014.
68. Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia 2010; 24: 1934-1939.
69. Lacy MQ, Kumar SK, LaPlant BR, Laumann K, Gertz MA, Hayman SR et al. Pomalidomide plus low-dose dexamethasone (Pom/Dex) in relapsed myeloma: Long term follow up and factors predicing outcome in 345 patients. ASH Ann Meet Abstr 2012; 120: 201.
70. Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of 2 dosing strategies in dual-refractory disease. Blood 2011; 118: 2970-2975.
71. Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood 2013; 121: 1968-1975.
72. San-Miguel JF, Weisel KC, Moreau P, Lacy M, Song KW, Delforge M et al. MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM). ASCO Meet Abstr 2013; 31(15-suppl): 8510.
73. Usmani SZ, Hansen E, Steward D, Waheed S, Panozzo SB, Petty NM et al. Phase II study of pomalidomide (Pom) in genomically defined high risk relapsed and refractory multiple myeloma (RRMM). ASH Ann Meet Abstr 2012; 120: 4083.
74. Ponisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-A randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132: 205-212.
75. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS et al. Bendamustine combined with bortezomib has efficacy in patients with relapsed or refractory multiple myeloma: A phase 1/2 study. ASH Ann Meet Abstr 2011; 118: 1857.
76. Poenisch W, Bourgeois M, Wang S-Y, Heyn S, Jaekel N, Braunert L et al. Bortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory/relapsed multiple myeloma. ASH Ann Meet Abstr 2007; 110: 2723.
77. Ludwig H, Kasparu H, Linkesch W, Thaler J, Greil R, Leitgeb C et al. Bortezomib-bendamustine-dexamethasone in patients with relapsed/refractory multiple myeloma (MM) shows marked efficacy and is well tolerated, but assessment of pnp symptoms shows significant discrepancies between patients and physicians. ASH Ann Meet Abstr 2011; 118: 2928.
78. Hrusovsky I, Heidtmann H-H. Combination therapy of bortezomib with bendamustin in elderly patients with advanced multiple myeloma. Clinical Observation. ASH Ann Meet Abstr 2007; 110: 4851.
79. Rodon P, Hulin C, Pegourie B, Tiab M, Anglaret B, Ben-Boubker L et al. Bendamustine, bortezomib and dexamethasone (BVD) in elderly mm progressive after 1st line therapy (IFM 2009-01 Trial): Predictive factors of defavourable outcome. Haematologica 2013; 98: Abstract P231.
80. Ponisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: Results of a Phase I clinical trial. Br J Haematol 2008; 143: 191-200.
81. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 2011; 155: 632-634.
82. Grey-Davies E, Bosworth JL, Boyd KD, Ebdon C, Saso R, Chitnavis D et al. Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma. Br J Haematol 2012; 156: 552-555; Author reply 555.
83. Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: Results of phase 1/2 open-label, dose escalation study. Blood 2012; 119: 4608-4613.
84. Ponisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA et al. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: Final results of a phase 1 clinical trial OSHO - #077. Br J Haematol 2013; 162: 202-209.
85. Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res 2013; 19: 3019-3031.
86. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol 2011; 154: 745-754.
87. van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. Leukemia 2012; 26: 199-213.
88. Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H et al. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 2012; 120: 552-559.
89. Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012; 30: 1953-1959.
90. Richardson PG, Jagannath S, Moreau P, Jakubowiak A, Raab MS, Facon T et al. A phase 2 study of elotuzumab (Elo) in combination with lenalidomide and lowdose dexamethasone (Ld) in patients (pts) with relapsed/refractory multiple myeloma (R/R MM): Updated results. ASH Ann Meet Abstr 2012; 120: 202.
91. Facon T, Richardson PG, Jagannath S, Moreau P, Jakubowiak A, Raab M et al. Phase I/II study of elotuzumabplus lenalidomide/dexamethasone in relapsed/ refractory multiple myeloma: Updated phase ii results and phase i/ii long term safety. Haematologica 2013; 98: Abstract 228.
92. Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson PG. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase i/ii study. ASH Ann Meet Abstr 2012; 120: 73.
93. Lokhorst HM, Plesner T, Gimsing P, Nahi H, Minnema M, Lassen UN et al. Phase I/II dose-escalation study of daratumumab in patients with relapsed or refractory multiple myeloma. ASCO Meet Abstr 2013; 31(15-suppl): 8512.
94. Chanan-Khan A, Wolf JL, Garcia J, Gharibo M, Jagannath S, Manfredi D et al. Efficacy analysis from phase I study of lorvotuzumab mertansine (IMGN901), used as monotherapy, in patients with heavily pre-Treated CD56-Positive multiple myeloma - a preliminary efficacy analysis. ASH Ann Meet Abstr 2010; 116: 1962.
95. Jagannath S, Chanan-Khan A, Heffner LT, Avigan D, Zimmerman TM, Lonial S et al. BT062, an antibody-drug conjugate directed against CD138, Shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma. ASH Ann Meet Abstr 2011; 118: 305.
96. Heffner LT, Jagannath S, Zimmerman TM, Lee KP, Rosenblatt J, Lonial S et al. BT062, an antibody-drug conjugate directed against CD138, given weekly for 3 weeks in each 4 week cycle: Safety and further evidence of clinical activity. ASH Ann Meet Abstr 2012; 120: 4042.
97. Bensinger W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol 2012; 159: 58-66.
98. Hussein M, Berenson JR, Niesvizky R, Munshi N, Matous J, Sobecks R et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 2010; 95: 845-848.
99. Raje N, Faber Jr EA, Richardson PG, Schiller GJ, Hohl RJ, Cohen AD et al. Phase 1 study of tabalumab, a human anti-BAFF Antibody and bortezomib in patients with previously-Treated multiple myeloma. ASH Ann Meet Abstr 2012; 120: 447.
100. Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A et al. A phase 2 multicenter study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. ASH Ann Meet Abstr 2011; 118: 3971.
101. Rossi J-F, Manges RF, Sutherland HJ, Jagannath S, Voorhees P, Sonneveld P et al. Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. ASH Ann Meet Abstr 2008; 112: 867.
102. San Miguel J, Blade J, Samoilova OS, Novgorod N, Shpilberg O, Grosicki S et al. Randomized, open-label, phase 2 study of siltuximab (an anti-IL-6 Mab) and bortezomib-melphalan-prednisone versus bortezomib-melphalan-prednisone in patients with previously untreated multiple myeloma. Haematologica 2013; 98: Abstract P225.
103. Benson Jr DM, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagganath S, Abonour R et al. A phase I trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 2012; 120: 4324-4333.
104. Benson Jr DM, Cohen AD, Munshi NC, Jagannath S, Spitzer G, Hofmeister CC et al. A phase I trial of the anti-inhibitory KIR antibody, IPH2101, and lenalidomide in multiple myeloma: Interim results. ASH Ann Meet Abstr 2012; 120: 4058.
105. Ocio EM, San Miguel JF. The DAC system and associations with multiple myeloma. Invest New Drugs 2010; 28(Suppl 1): S28-S35.
106. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: Overview and perspectives. Mol Cancer Res 2007; 5: 981-989.
107. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets?. Cancer Lett 2009; 277: 8-21.
108. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-Tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-3449.
109. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781-5789.
110. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540-545.
111. Khan SB, Maududi T, Barton K, Ayers J, Alkan S. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. Br J Haematol 2004; 125: 156-161.
112. Todoerti K, Barbui V, Pedrini O, Lionetti M, Fossati G, Mascagni P et al. Pleiotropic anti-myeloma activity of ITF2357: Inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. Haematologica 2010; 95: 260-269.
113. Chesi M, Matthews GM, Garbitt VM, Palmer SE, Shortt J, Lefebure M et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012; 120: 376-385.
114. Galli M, Salmoiraghi S, Golay J, Gozzini A, Crippa C, Pescosta N et al. A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann Hematol 2010; 89: 185-190.
115. Niesvizky R, Ely S, Mark T, Aggarwal S, Gabrilove JL, Wright JJ et al. Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011; 117: 336-342.
116. Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008; 49: 502-507.
117. Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR et al. Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma 2012; 53: 1820-1823.
118. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15: 5250-5257.
119. Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011; 118: 6274-6283.
120. San Miguel J, Sezer O, Gunther A, Siegel D, Blade J, Leblanc R et al. Phase Ib dose-escalation study of oral panobinostat and iv bortezomib in patients with relapsed or relapsed and refractory multiple myeloma: Updated results. Haematol IMW Meet Abstr 2011; 96(Supp-1): P-238.
121. Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 319-324.
122. Leleu X, Touzeau C, Benboubker L, Facon T, Delain M, Fourneau N et al. Phase Ib dose escalation study of oral quisinostat, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone for patients with relapsed multiple myeloma. ASCO Meet Abstr 2013; 31(15-suppl): 8530.
123. Dimopoulos MA, Jagannath S, Yoon S-S, Siegel DS, Lonial S, Hajek R et al. Vantage 088: Vorinostat in combination with bortezomib in patients with relapsed/refractory multiple myeloma: Results of a global, randomized phase 3 trial. ASH Ann Meet Abstr 2011; 118: 811.
124. Siegel DS, Dimopoulos MA, Yoon S-S, Laubach JP, Kaufman JL, Goldschmidt H et al. Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: Final study results of a global phase 2b trial. ASH Ann Meet Abstr 2011; 118: 480.
125. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C et al. PANORAMA 2: Panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013; 122: 2331-2337.
126. Raje N, Hari PN, Vogl DT, Jagannath S, Orlowski RZ, Supko JG et al. Rocilinostat (ACY-1215), a selective HDAC6 inhibitor, alone and in combination with bortezomib in multiple myeloma: Preliminary results from the first-in-humans phase I/II study. ASH Ann Meet Abstr 2012; 120: 4061.
127. Raje N, Mahindra A, Vogl D, Voorhees PM, Bensinger W, Parameswaran RV et al. New drug partner for combination therapy in multiple myeloma (MM): Development of ACY-1215, a selective histone deacetylase 6 inhibitor alone and in combination with bortezomib or lenalidomide. Haematologica 2013; 98: Abstract P765.
128. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J. Cyclin D dysregulation: An early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303.
129. Stewart AK, Vij R, Laubach JP, Hofmeister CC, Hagerty R, Dueck AC et al. Phase I study of aurora kinase inhibitor MLN8237 and bortezomib in relapsed or refractory multiple myeloma. ASH Ann Meet Abstr 2012; 120: 1859.
130. Shah JJ, Zonder J, Cohen A, Orlowski RZ, Alexanian R, Thomas SK et al. ARRY-520 shows durable responses in patients with relapsed/refractory multiple myeloma in a phase 1 dose-escalation study. ASH Ann Meet Abstr 2011; 118: 1860.
131. Shah JJ, Zonder JA, Cohen A, Bensinger W, Kaufman JL, Orlowski RZ et al. The novel KSP inhibitor ARRY-520 is active both with and without low-dose dexamethasone in patients with multiple myeloma refractory to bortezomib and lenalidomide: Results from a phase 2 study. ASH Ann Meet Abstr 2012; 120: 449.
132. Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood 2011; 117: 3847-3857.
133. Kumar SK, LaPlant BR, Chng WJ, Zonder JA, Callander N, Roy V et al. Phase 1/2 trial of a novel CDK inhibitor dinaciclib (SCH727965) in patients with relapsed multiple myeloma demonstrates encouraging single agent activity. ASH Ann Meet Abstr 2012; 120: 76.
134. Scheid C, Reece D, Beksac M, Spencer A, Callander N, Sonneveld P et al. A phase 2, multicenter, nonrandomized, open-label study of dovitinib (TKI258) in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. ASH Ann Meet Abstr 2012; 120: 4055.
135. Trudel S, Bergsagel PL, Singhal S, Niesvizky R, Comenzo RL, Bensinger WI et al. A phase I study of the safety and pharmacokinetics of escalating doses of MFGR1877S, a fibroblast growth factor receptor 3 (FGFR3) antibody, in patients with relapsed or refractory t(4;14)-positive multiple myeloma. ASH Ann Meet Abstr 2012; 120: 4029.
136. Arnulf B, Ghez D, Leblond V, Choquet S, Belhadj K, Macro M et al. FGFR3 tyrosine kinase inhibitor AB1010 as treatment of t(4;14) multiple myeloma. Blood 2007; 110: 128a Abstract 413.
137. Dispenzieri A, Gertz MA, Lacy MQ, Geyer SM, Greipp PR, Rajkumar SV et al. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma 2006; 47: 39-42.
138. Wildes TM, Procknow E, Gao F, Dipersio JF, Vij R. Dasatinib in relapsed or plateauphase multiple myeloma. Leuk Lymphoma 2009; 50: 137-140.
139. Facon T, Leleu X, Stewart AK, Spencer A, Rowlings P, Hulin C et al. Dasatinib in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: Preliminary results of a phase I study. ASH Ann Meet Abstr 2009; 114: 1876.
140. Callander NS, Markovina S, Juckett MB, Wagner E, Kolesar J, Longo W et al. The addition of bevacizumab (B) to lenalidomide and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma (NCI#7317). ASH Ann Meet Abstr 2009; 114: 3885.
141. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
142. Moreau P, Cavallo F, Leleu X, Hulin C, Amiot M, Descamps G et al. Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia 2011; 25: 872-874.
143. von Tresckow B, Boll B, Eichenauer DA, Peine D, Knop S, Goebeler M et al. A phase II clinical trial of the anti-EGFR antibody cetuximab in patients with refractory or relapsed multiple myeloma: Final results. ASH Ann Meet Abstr 2011; 118: 3965.
144. Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL et al. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol 2011; 86: 573-578.
145. Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M et al. Tanespimycin with bortezomib: Activity in relapsed/refractory patients with multiple myeloma. Br J Haematol 2010; 150: 428-437.
146. Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M et al. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: Results of a phase 1/2 study. Br J Haematol 2011; 153: 729-740.
147. Richardson P, Lonial S, Jakubowiak A, Krishnan A, Wolf J, Densmore J et al. Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): Promising activity as combination therapy with manageable toxicity. Blood 2007; 110: 353a Abstract 1164.
148. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: Results of a multicenter phase I/II trial. J Clin Oncol 2011; 29: 4243-4249.
149. Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M et al. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/ refractory multiple myeloma: A Phase I Multiple Myeloma Research Consortium study. Br J Haematol 2012; 158: 472-480.
150. Spencer A, Yoon S-S, Harrison SJ, Morris S, Smith D, Freedman SJ et al. Novel AKT inhibitor GSK2110183 shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. preliminary results from a phase I first-Time-inhuman study. ASH Ann Meet Abstr 2011; 118: 1856.
151. Guenther A, Baumann P, Burger R, Klapper W, Schmidmaier R, Gramatzki M. Single-Agent everolimus (RAD001) in patients with relapsed or refractory multiple myeloma: Final results of a phase I study. ASCO Meet Abstr 2010; 28(15-suppl): 8137.
152. Farag SS, Zhang S, Jansak BS, Wang X, Kraut E, Chan K et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 2009; 33: 1475-1480.
153. Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M et al. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: A multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011; 12: 263-272.
154. Mahindra A, Richardson PG, Hari P, Sohani AR, Laubach JP, Burke J et al. Updated results of a phase I study of RAD001 in combination with lenalidomide in patients with relapsed or refractory multiple myeloma with pharmacodynamic and pharmacokinetic analysis. ASH Ann Meet Abstr 2010; 116: 3051.
155. Yee AJ, Mahindra AK, Richardson PG, Cirstea DD, Scullen TA, Rodig SJ et al. Biomarker correlation with outcomes in patients with relapsed or refractory multiple myeloma on a phase I study of everolimus in combination with lenalidomide. ASH Ann Meet Abstr 2011; 118: 3966.
156. Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: Evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol 2011; 29: 3427-3434.
157. Ghobrial IM, Siegel D, Vij R, Wolf JL, Berdeja JG, Matous JV et al. MLN0128 (INK128), an investigational oral dual TORC1/2 inhibitor, in patients (pts) with relapsed or refractory multiple myeloma (MM), non-hodgkin's lymphoma (NHL), or Waldenstrom macroglobulinemia (WM): Preliminary results from a phase 1 dose-escalation study. ASH Ann Meet Abstr 2012; 120: 4038.
158. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004; 103: 3271-3277.
159. Holkova B, Badros AZ, Geller R, Voorhees PM, Zingone A, Korde N et al. A phase II study of the MEK 1/2 inhibitor AZD6244 (selumetinib, ARRY-142866) in relapsed or refractory multiple myeloma. ASH Ann Meet Abstr 2011; 118: 2931.
160. Siegel DS, Krishnan A, Lonial S, Chatta G, Alsina M, Jagannath S et al. Phase II trial of SCIO-469 as monotherapy (M) or in combination with bortezomib (MB) in relapsed refractory multiple myeloma (MM). Blood 2006; 108: Abstract 3580.
161. Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J et al. Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res 2010; 16: 3260-3269.
162. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
163. Lehners N, Andrulis M, Capper D, von Deimling A, Ho AD, Goldschmidt H et al. BRAF V600E mutations in multiple myeloma: Clinical and therapeutic implications. ASH Ann Meet Abstr 2012; 120: 4040.
164. Chen W, Qiu L, Hou J, Zhang X, Ke X, Wang Z et al. Phase Ib study of recombinant circularly permuted TRAIL (CPT) in relapsed or refractory multiple myeloma patients. ASH Ann Meet Abstr 2012; 120: 1857.
165. Chen W, Qiu L, Hou J, Zhao Y, Pan L, Yang S et al. Recombinant circularly permuted TRAIL (CPT) for the treatment of relapsed or refractory multiple myeloma: An open-label, multicenter phase II clinical trial. ASH Ann Meet Abstr 2012; 120: 78.
166. Chen W, Hou J, Zhao Y, Qiu L, Ke X, Wang Z et al. Circularly permuted TRAIL (CPT) combined with thalidomide for the treatment of relapsed or refractory multiple myeloma: An open-label, multicenter phase II clinical trial. ASH Ann Meet Abstr 2012; 120: 2958.
167. Ocio EM, De La Rubia J, Oriol-Rocafiguera A, Blade J, Rodriguez J, Coronado C et al. Phase II optimization, open-label clinical trial of zalypsis(R) (PM00104) in relapsed/ refractory multiple myeloma patients. ASH Ann Meet Abstr 2012; 120: 4041.
168. Neri P, Duggan P, Gratton K, Ren L, Johnson J, Slaby J et al. Phase I study of the PARP1-2 inhibitor veliparib in combination with bortezomib in patients with relapsed or refractory multiple myeloma. ASH Ann Meet Abstr 2012; 120: 1862.
169. Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011; 25: 1533-1542.
170. Ghobrial IM, Laubach J, Armand P, Boswell E, Hanlon C, Chuma S et al. Phase I study of TH-302, an investigational hypoxia-Targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma. ASCO Meet Abstr 2013; 31(15-suppl): 8602.
171. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013; 19: 2048-2060.
172. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19: 3640-3648.
173. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011; 34: 409-418.
174. Benson Jr DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116: 2286-2294.
175. O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009; 15: 7085-7091.
176. Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL et al. A phase I single-Agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res 2012; 18: 4830-4840.
177. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T et al. An open-label single-Arm pilot phase II study (PX-171-003-A0) of low-dose, single-Agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 310-318.
178. diCapua Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Jagannath S et al. Results of PX-171-003-A1, an open-label, single-Arm, phase 2 (Ph 2) Study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). ASH Ann Meet Abstr 2010; 116: 985.
179. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269-3276.
180. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008; 141: 41-51.
181. Richardson PG, Siegel DS, Vij R, Hofmeister CC, Jagannath S, Chen C et al. Randomized, open label phase 1/2 study of pomalidomide (POM) alone or in combination with low-dose dexamethasone (LoDex) in patients (Pts) with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide (LEN) and bortezomib (BORT): Phase 2 results. ASH Ann Meet Abstr 2011; 118: 634.
182. Siegel DSD, Richardson PGG, Vij R, Hofmeister CC, Baz RC, Jagannath S et al. Long-Term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial. ASCO Meet Abstr 2013; 31(15-suppl): 8588.
183. Mark TM, Boyer A, Rossi AC, Shah M, Pearse RN, Zafar F et al. ClaPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. ASH Ann Meet Abstr 2012; 120: 77.
184. Hilger JD, Berenson JR, Klein LM, Bessudo A, Rosen PJ, Eshaghian S et al. A phase I/II study (NCT01541332) of pomalidomide (POM), dexamethasone (DEX), and pegylated liposomal doxorubicin (PLD) for patients with relapsed/refractory (R/R) multiple myeloma (MM). ASCO Meet Abstr 2013; 31(15-suppl): 8598.
185. Richardson PGG, Hofmeister CC, Siegel DSD, Lonial S, Laubach J, Efebera YA et al. MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM). ASCO Meet Abstr 2013; 31(15-suppl): 8584.
186. Baz R, Shain KH, Alsina M, Nardelli LA, Nishihori T, Ochoa L et al. Oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone for relapsed and refractory myeloma: Report of the dose escalation cohort. ASH Ann Meet Abstr 2012; 120: 4062.
187. Larocca A, Montefusco V, Bringhen S, Rossi D, Crippa C, Mina R et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: A multicenter phase 1/2 open-label study. Blood 2013; 122: 2799-2806.
188. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 2012; 30: 1960-1965.
189. Berdeja JG, Hernandez-Ilizaliturri F, Chanan-Khan A, Patel M, Kelly KR, Running KL et al. Phase I study of lorvotuzumab mertansine (LM, IMGN901) in combination with lenalidomide (Len) and dexamethasone (Dex) in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma (MM). ASH Ann Meet Abstr 2012; 120: 728.
190. Agura E, Niesvizky R, Matous J, Munshi N, Hussein M, Parameswaran RV et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: Multiple responses observed in a phase 1b study. ASH Ann Meet Abstr 2009; 114: 2870.
191. Richardson P, Weber D, Mitsiades CS, Dimopoulos MA, Harousseau J-L, Houp J et al. A phase I study of vorinostat, lenalidomide, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: Excellent tolerability and promising activity in a heavily pretreated population. ASH Ann Meet Abstr 2010; 116: 1951.
192. Richter JR, Bilotti E, McBride L, Schmidt L, Gao Z, Tufail M et al. Salvage therapy with vorinostat, lenalidomide, and dexamethasone (ZRD) in lenalidomide/ dexamethasone relapsed/refractory multiple myeloma. ASH Ann Meet Abstr 2011; 118: 3986.
193. Mateos M, Spencer A, Taylor K, Lonial S, De La Rubia J, Facon T et al. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM). ASCO Meet Abstr 2010; 28(15-suppl): 8030.
194. Voorhees PM, Gasparetto C, Osman K, Richards KL, Ferraro M, Garcia R et al. Vorinostat in combination with pegylated liposomal doxorubicin (PLD) and bortezomib (B) in patients with relapsed/refractory multiple myeloma (R/R MM): Final results of a phase I study. ASH Ann Meet Abstr 2011; 118: 3985.
195. Siegel D, Bilotti E, McBride L, Richardson P, Schmidt L, Gao Z et al. Vorinostat overcomes resistance in patients with multiple myeloma refractory to bortezomib, lenalidomide and dexamethasone. Haematol IMW Meet Abstr 2011; 96(Supp-1): P-216.
196. Kaufman JL, Shah JJ, Laubach JP, Mitchell AR, Sharp C, Lewis C et al. Lenalidomide, bortezomib, and dexamethasone (RVD) in combination with vorinostat as front-line therapy for patients with multiple myeloma (MM): Results of a phase 1 study. ASH Ann Meet Abstr 2012; 120: 336.
197. Berenson JR, Yellin O, Kazamel T, Boccia RV, Matous J, Dressler K et al. A phase I/II study of oral melphalan (Mel) combined with panobinostat (Pan) for patients with relapsed or refractory (R/R) multiple myeloma (MM). Haematol IMW Meet Abstr 2011; 96(Supp-1): P-206.
198. Offidani M, Cavallo F, Polloni C, Liberati M, Ballanti S, Pulini S et al. Phase I-II study of melphalan, thalidomide and prednisone (MPT) combined with oral panobinostat in patients with relapsed/refractory MM. Haematol IMW Meet Abstr 2011; 96(Supp-1): P-191.
199. Niesvizky R, Lentzsch S, Badros AZ, Chanan-Khan AA, Singhal SB, Zonder JA et al. A phase I study of PD 0332991: Complete CDK4/6 inhibition and tumor response in sequential combination with bortezomib and dexamethasone for relapsed and refractory multiple myeloma. ASH Ann Meet Abstr 2010; 116: 860.
200. Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M et al. Tanespimycin monotherapy in relapsed multiple myeloma: Results of a phase 1 dose-escalation study. Br J Haematol 2010; 150: 438-445..